Passage Bio and Remix Therapeutics Announce Merger Agreement
Passage Bio and Remix Therapeutics have entered into a definitive all-stock merger agreement to form a combined company operating as Remix Therapeutics, Inc., trading under the ticker RMTX on Nasdaq. The merger strengthens the company's pipeline focused on RNA processing modulation, notably advancing REM-422, an oral mRNA degrader targeting MYB imp…